Motoi Takeuchi

N- and O-glycome analysis of serum and urine from bladder cancerpatients using a high-throughput glycoblotting method

Purpose: To develop novel diagnostic biomarkers for Bladder Cancer (BC), we concurrently evaluated serum and urine glycans in BC patients by utilizing a recently established glycoblotting method. Experiments: N- and O-glycan levels in whole serum from 45 and 13 male patients diagnosed with BC were analyzed. As a control, 29 and 10 patients with benign prostatic hyperplasia (BPH) were also studied and the results were compared. Furthermore, urine N- and O-glycome from 8 patients with muscle-invasive BC and 11 with BPH were analyzed. In serum N-glycome analysis the area-under-the-curve (AUC) value was calculated by in house R software. In the other cases JMP, version 10.0.2 software package (SAS, Cary, NC) was used and p <0.05 was considered statistically significant. Results: The expression level of three N-glycans significantly increased in sera of BC patients. All of them had highly branched and sialylated structures with core-Fuc. The levels of three O-glycans were significantly higher in BC than in the control. In examination of urine samples, 16 N-glycans were significantly elevated in BC as compared to the control. Although 11 O-glycans were detected in urine samples, there was no significant difference in the expression levels. Conclusions: The levels of highly branched, sialylated N-glycans and early sialylated O-glycans were increased in sera of BC patients. Moreover, we found that N-glycans increased in urine more than in serum of BC patients. These results suggest that the glycome change in urine directly results from glycoproteins that exist in BC cells. Thus, further large-scale glycan profiling will provide novel biomarkers for diagnosing BC in the near future.

Contemporary Patients With LUTS/BPH Requiring Prostatectomy Have Long-term History of Treatment With α1-Blockers and Large Prostates Compared With Past Cases

OBJECTIVES To retrospectively investigate the characteristics of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia for which surgery was needed during the past 20 years. In particular, the chronologic change in prostate volume at surgery and the status of alpha(1)-blocker use before surgery and its duration were studied. METHODS The data from 371 consecutive patients with lower urinary tract symptoms/benign prostatic hyperplasia who had undergone surgery in our institute from 1987 through 2006 were retrospectively analyzed. The number of surgeries, type of surgical procedure, content and duration of medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia before surgery, prostate volume on transrectal ultrasonography at baseline and at surgery, and the weight of the removed tissue were determined from the medical charts. RESULTS The number of surgeries suddenly began to decrease between 1987 and 1990 and again from 1991 to 1994, probably owing to the introduction of 2 nonselective alpha(1)-blockers at those times in Japan. The percentage of use of alpha(1)-blockers before surgery and the duration of use increased in each period. More than 80% of recent patients had received alpha(1)-blockers before surgery, with an average duration of 3 years. Recent patients had a large prostate volume at baseline and at surgery compared with previous patients. Corresponding to the large prostate, open subcapsular prostatectomy was indicated in 18% of the recent patients. CONCLUSIONS Patients with surgical treatment after long-term use of alpha(1)-blockers had large prostates at baseline and at surgery. Although alpha(1)-blockers delayed the need for surgery by a few years, patients with a large prostate volume might finally need to undergo surgery.

Impact of visceral fat ratio on sleep-related erection: a retrospective study of elderly patients.

To investigate the impact of visceral fat accumulation on the preoperative erectile function of elderly patients undergoing radical prostatectomy.